Cidara Therapeutics, Inc.
Introduction
This page provides a comprehensive analysis of the known insider trading history of Levine James E.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.
Average Trade Profitability
The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.
If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.
Update Frequency: Daily
Companies with Reported Insider Positions
The SEC filings indicate Levine James E. has reported holdings or trades in the following companies:
| Security | Title | Latest Reported Holdings |
|---|---|---|
| US:CRDF / Cardiff Oncology, Inc. | Chief Financial Officer | 67,716 |
| US:CDTX / Cidara Therapeutics, Inc. | Chief Financial Officer | 130,000 |
| US:VRNM / Verenium Corp | President & CEO, Director | 0 |
How to Interpret the Charts
The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Levine James E.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.
Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.
However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.
The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.
Insider Purchases CDTX / Cidara Therapeutics, Inc. - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CDTX / Cidara Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales CDTX / Cidara Therapeutics, Inc. - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CDTX / Cidara Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market sales that were not part of an automatic trading plan.
| Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Purchases CRDF / Cardiff Oncology, Inc. - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CDTX / Cidara Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales CRDF / Cardiff Oncology, Inc. - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CDTX / Cidara Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market sales that were not part of an automatic trading plan.
| Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Trading History
This table shows the complete list of insider trades made by Levine James E. as disclosed to the Securities Exchange Commission (SEC).
| File Date | Tran Date | Form | Ticker | Security | Code | Shares | Remaining Shares | Percent Change |
Share Price |
Tran Value |
Remaining Value |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-18 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 2,400 | 67,716 | 3.67 | 5.00 | 12,000 | 338,580 | |
| 2024-12-18 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 2,752 | 65,316 | 4.40 | 5.42 | 14,905 | 353,765 | |
| 2024-12-18 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 2,564 | 62,564 | 4.27 | 3.83 | 9,820 | 239,620 | |
| 2022-09-19 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 30,000 | 60,000 | 100.00 | 1.56 | 46,710 | 93,420 | |
| 2022-03-10 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Stock Options |
A - Award | 170,016 | 560,016 | 43.59 | ||||
| 2021-09-13 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 5,000 | 30,000 | 20.00 | 6.32 | 31,600 | 189,600 | |
| 2021-09-13 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 5,000 | 25,000 | 25.00 | 6.35 | 31,750 | 158,750 | |
| 2021-09-13 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 10,000 | 20,000 | 100.00 | 6.38 | 63,800 | 127,600 | |
| 2021-09-13 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 5,000 | 10,000 | 100.00 | 6.75 | 33,750 | 67,500 | |
| 2021-09-13 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
P - Purchase | 5,000 | 5,000 | 6.62 | 33,100 | 33,100 | ||
| 2021-07-12 |
|
4 | CRDF |
Cardiff Oncology, Inc.
Common Stock |
A - Award | 390,000 | 390,000 | |||||
| 2021-03-19 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Employee Stock Option (right to buy) |
A - Award | 130,000 | 130,000 | |||||
| 2020-11-12 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Common Stock |
P - Purchase | 50,000 | 50,000 | 2.01 | 100,720 | 100,720 | ||
| 2020-03-23 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | 110,000 | 110,000 | |||||
| 2020-03-23 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Common Stock |
A - Award | 25,000 | 61,891 | 67.77 | ||||
| 2020-03-23 |
|
4/A | CDTX |
Cidara Therapeutics, Inc.
Common Stock |
P - Purchase | 30,000 | 30,000 | 1.91 | 57,240 | 57,240 | ||
| 2020-01-30 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Subscription Rights (right to buy) |
X - Other | -6,891 | 0 | -100.00 | ||||
| 2020-01-30 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Common Stock |
X - Other | 6,891 | 211,891 | 3.36 | 2.51 | 17,296 | 531,846 | |
| 2019-09-26 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Common Stock |
P - Purchase | 30,000 | 205,000 | 17.14 | 1.91 | 57,240 | 391,140 | |
| 2018-12-04 |
|
4 | CDTX |
Cidara Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 175,000 | 175,000 | |||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
D - Sale to Issuer | -16,875 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
D - Sale to Issuer | -20,833 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
D - Sale to Issuer | -129,695 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
D - Sale to Issuer | -444 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
D - Sale to Issuer | -10,937 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | -13,125 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | -34,796 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | -84,556 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | -24,063 | 0 | -100.00 | ||||
| 2013-11-04 |
|
4 | VRNM |
VERENIUM CORP
Common Stock |
D - Sale to Issuer | -109,166 | 0 | -100.00 | 4.00 | -436,664 | ||
| 2013-08-02 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
A - Award | 10,937 | 10,937 | |||||
| 2013-08-02 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
A - Award | 24,063 | 24,063 | |||||
| 2012-08-03 |
|
4 | VRNM |
VERENIUM CORP
Non-Qualified Stock Option (Right to Buy) |
A - Award | 16,875 | 16,875 | 4.23 | 71,381 | 71,381 | ||
| 2012-08-03 |
|
4 | VRNM |
VERENIUM CORP
Employee Stock Option (Right to Buy) |
A - Award | 13,125 | 13,125 | 4.23 | 55,519 | 55,519 | ||
| 2012-05-16 |
|
4 | VRNM |
VERENIUM CORP
Common Stock |
P - Purchase | 4,994 | 109,166 | 4.79 | 3.65 | 18,228 | 398,456 |
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
